(Washington, D.C.): Earlier today, the Department of Justice under the Trump Administration requested a federal court pause the case in Louisiana v. FDA and deny the client immediate relief pending the Food and Drug Administration (FDA) review of the abortion pill, mifepristone. There is no public evidence that this review is actively being conducted.
Sarah Zagorski, Senior Director of Public Relations & Communications for Americans United for Life (AUL), stated, “Whereas just days ago, the Administration assured the Pro-Life movement of its bona fides, now, by requesting a delay in this case, it’s sending just the opposite message – cold comfort to the victims of the abortion pill. By delaying the case, they are prolonging the plight of women victimized by the deregulated pills and enabling abusers to continue their misdeeds. If the Trump Administration refuses to act immediately to end this abuse, it will cement this injustice as its legacy. No political agenda is above the inherent moral value of life, both women and their unborn babies.”
Steven H. Aden, Chief Legal Officer & General Counsel for AUL, added, “The FDA’s filing today is just another episode in the continuing saga of the Trump Administration’s lawyers seeking legal delays while administration officials make promises of action on chemical abortion. Pro-life Americans are growing increasingly frustrated with the failure to meet words with action.”
For more information or to arrange an interview with AUL, contact Gavin Oxley at press@aul.org or 202-987-3321.
Since 1971, Americans United for Life (AUL) has advanced the human right to life in culture, law, and policy by equipping advocates and lawmakers with the facts and strategies that change hearts and minds and protect human life. The first national pro-life organization in the country, AUL is a nonprofit, public-interest law and policy organization with a four-star rating from Charity Navigator.
